PRTA: Prothena Corporation P/S Multiple
Prothena Corporation (PRTA) generates revenue through royalties and payments from major partners in the therapy of amyloid pathologies. The P/S multiple trend confirms market optimism, where 8.00 characterizes this valuation parameter. High authority in neuromedicine strengthens shareholder confidence, although geopolitical tensions and logistical complexities may hinder the conduct of overseas clinical trials and the delivery of components.
Metric breakdowns and analytics for Prothena Corp (PRTA)
- stock price and consensus target price:
- market capitalization information:
- balance sheet equity data:
- business debt structure and liquidity details:
- earnings and valuation multiples information:
PRTA - Net Profit|Projected Future Earnings Prothena Corporation|PRTA - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Prothena|PRTA - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Prothena Corp|PRTA - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Prothena|PRTA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months prothena.com|PRTA - Earnings per share growth in current year|Net earnings per share change forecast for next year Prothena Corporation
- issuer revenue and sales details:
Fundamental company analysis:prothena.com - PRTA
The P/S multiple determines the market value of a business relative to its annual sales volume, allowing for an assessment of asset monetization efficiency without considering operating expenses. For Prothena Corporation (PRTA), whose developments in neurodegenerative diseases are in late-stage trials, the company's smoothed P/S reflects market expectations for the future commercialization of breakthrough therapeutic antibodies before products reach the mass sales stage.
Competitors of Prothena Corporation
biogen.com - Market Cap to Revenue Ratio|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|P/S Multiple Regencell Bioscience Ltd RGC|AXSM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|XENE: P/S Multiple|Market Cap to Revenue vikingtherapeutics.com|Price-to-Revenue Ratio Supernus|Price to Sales Catalyst Pharma CPRX|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Biohaven Ltd. BHVN|AMLX (amylyx.com) - Price-to-Sales Ratio|TRVI - Price-to-Revenue Ratio|Price to Sales Praxis Precision Medicines Inc|Anavex Corp (AVXL) - Price-to-Revenue Ratio|CeriBell EEG - Market Capitalization-to-Revenue Ratio|ALEC (Alector Inc.) - P/S Multiple|P/S Multiple annexonbio.com|Market Cap to Revenue OMER (Omeros Corporation)|Market Cap to Sales Volume NGNE|P/S Multiple ACIU (AC Immune Corp)|Price-to-Revenue Coefficient Voyager Corp (VYGR)|NMRA - Price-to-Revenue Ratio|Price to Sales scilexholding.com|Tevogen Bio (TVGN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio ACOG|Price-to-Revenue Ratio Cognition Therapeutics, Inc.|Inhibikase Pharma - Price-to-Sales Ratio|Price-to-Revenue Ratio Cassava Sciences, Inc. (SAVA)|ASRT (assertiotx.com) - Market Capitalization-to-Revenue Ratio|Coya Therapeutics - Market Cap to Revenue|Market Cap to Sales Volume VTGN (VistaGen Therapeutics, Inc.)|Ovid Rx - P/S Multiple|ABOS - P/S Multiple|CervoMed Inc. (CRVO) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio ATHE|CLNN (Clene Inc) - P/S Multiple|Price to Sales PepGen Corp PEPG|Market Cap to Revenue JUNS (Jupiter Neurosciences)|P/S Multiple Relmada Corp (RLMD)|Price-to-Revenue Ratio Annovis Bio, Inc. ANVS|Market Capitalization-to-Revenue Ratio GRCE|AIFF - Price-to-Revenue Ratio|Price to Sales Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Price-to-Revenue Ratio|Price-to-Sales Ratio RVPH (Reviva Pharmaceuticals, Inc.)|Price-to-Revenue Ratio MetaVia Inc.|NRXS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Helius Medical (HSDT)|PASG - Price to Sales|Neuphoria Therapeutics - Market Cap to Revenue|Market Cap to Sales Volume NERV (Minerva)|Athira Pharma, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio ADXN (addextherapeutics.com)|ALZN: P/S Multiple|Price to Sales Cyclerion Therapeutics, Inc. (CYCN)|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Market Cap to Revenue Ratio KTTA (Pasithea)|P/S Multiple CRGT|P/S Multiple avenuetx.com (ATXI)|BrainStorm Cell Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CARA|Chromocell Therapeutics Corporation - P/S Multiple|Eliem Therapeutics (ELYM) - Market Cap to Revenue|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Price to Sales longboardpharma.com (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE: Price-to-Sales Ratio|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|trevena.com (TRVN) - Price to Sales|VIGL - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio WENA (anewmeds.com)|CERE: P/S Multiple
